We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Booster shot

14 February 2020 By Aimee Donnellan

China is the drugmaker’s second biggest market by sales, making the outbreak a bigger issue than for peers. But revenue there disappointed anyway, as did overall cancer drug sales. Pharma’s competitive pressures are making it harder for CEO Pascal Soriot to please investors.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)